Close
Novotech
Jabsco PureFlo 21 Single Use

Questex Acquires ExL Events

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Structural Pricing Pressure is Reshaping Pharma in 2026

In 2026, global pricing pressure in the pharmaceutical sector has shifted from a temporary, cyclical issue to a structural constraint. Explore how U.S. reforms, European reference pricing, and biosimilar competition are forcing companies to embed pricing risk into core strategy.

Merck Targets $70B Revenue in 2026 with Cidara Deal

Merck’s roughly $9.2 billion acquisition of Cidara Therapeutics and its $70 billion revenue ambition mark a strategic pivot toward respiratory vaccines and antivirals. Explore how this deal reshapes Merck’s portfolio and signals a broader industry shift toward targeted M&A to offset patent cliffs.

U.S. Drug Pricing Reset Becomes Real in 2026

In 2026, U.S. drug pricing finally moved from policy debate to P&L impact. The first set of Medicare “maximum fair prices” and Most‑Favoured‑Nation–style reference pricing are reshaping pharma margins and launch strategies.
- Advertisement -

Questex, a leading global business information and events company announced it has acquired ExL Events, Inc., expanding Questex’s presence in the global pharmaceutical, life science and healthcare markets.

ExL Events, founded in 2004 as ExL Pharma, is the industry leader in developing innovative, educational conferences that serve the pharmaceutical, life science and healthcare communities. Kerry Gumas, Questex President and Chief Executive Officer, said ExL will complement the services currently provided to those markets by Questex’s Fierce Life Science & Healthcare group of digital media titles and events.

The founders of ExL Events, Bryon Main, President and Chief Executive Officer, and Ethan Denkensohn, Chief Financial and Operating Officer, will continue to lead the organization and retain their existing staff. ExL Events, which will continue to operate from its New York headquarters, produces more than 70 annual events in the United States, Europe and Asia for pharmaceutical, biotechnology, medical device, diagnostics and contract research organizations; hospitals and physicians; and others.

“For the last 12 years, ExL Events has served the informational and networking needs of the dynamic and rapidly evolving global healthcare and pharmaceutical sectors through high-quality conferences that deliver important topical information and interactive networking opportunities,” said Main. “Having Questex’s many resources at our fingertips will fuel investment and global expansion opportunities for ExL Events. We look forward to working together to drive growth and innovation for the business and our customers.”

“With access to the media and information resources of the company, notably the Fierce LifeSciences & Healthcare group, we will have the opportunity to add value to our client solutions offering a strong combination of face-to-face events and year-round marketing, lead-generation, online learning and other information products to our clients and audiences. Going forward, we will remain completely focused on meeting the needs of our clients, and we will continue to innovate, bringing new events and services to market in each of our main business areas,” said Denkensohn of ExL Events.

“We are pleased to welcome Bryon, Ethan and the entire ExL Events team to the company,” said Gumas. “They have done an excellent job in building ExL Events into a high-service, high-value producer of events, which we believe will be well complemented by our industry-leading portfolio of digital media titles serving the industry.”

About Questex
Questex is a leading global business information and events company serving corporate and government clients and industries that are driving economic growth and business innovation around the world.

The company drives business investment, innovation and demand-creation in the markets it serves by bringing together investors, buyers, sellers and professionals through its over 100 trade shows, conferences and other business events, informing them through more than 100 business media and information products and supporting clients with a comprehensive platform of marketing solutions. Questex’s industry-focused business units include Life Sciences & Healthcare, Hospitality & Travel, Beauty & Wellness, and Technology & Telecom groups.

Questex is headquartered in Newton, Massachusetts. The company employs more than 350 dedicated professional staff members, who are located in offices throughout the United States, Europe and the Asia-Pacific region

 

 

Company: ExL Events


ExL Events develops engaging, content-driven conferences and partnered events for dynamic industry audiences, including pharmaceutical, biotechnology, medical device, diagnostic and contract research organizations; hospital networks; physicians; and communications and other entities. Behind our diverse event portfolio, our experienced team conducts extensive market research and targeted outreach. The results translate into innovative, high-quality events that facilitate the exchange of critical information between industry professionals and suppliers who support shared goals.

Send Enquiry for this story

By submitting this form you agree to allow www.worldpharmatoday.com to contact you regarding your enquiry.
See our Privacy Policy to learn more.

Latest stories

Related stories

Structural Pricing Pressure is Reshaping Pharma in 2026

In 2026, global pricing pressure in the pharmaceutical sector has shifted from a temporary, cyclical issue to a structural constraint. Explore how U.S. reforms, European reference pricing, and biosimilar competition are forcing companies to embed pricing risk into core strategy.

Merck Targets $70B Revenue in 2026 with Cidara Deal

Merck’s roughly $9.2 billion acquisition of Cidara Therapeutics and its $70 billion revenue ambition mark a strategic pivot toward respiratory vaccines and antivirals. Explore how this deal reshapes Merck’s portfolio and signals a broader industry shift toward targeted M&A to offset patent cliffs.

U.S. Drug Pricing Reset Becomes Real in 2026

In 2026, U.S. drug pricing finally moved from policy debate to P&L impact. The first set of Medicare “maximum fair prices” and Most‑Favoured‑Nation–style reference pricing are reshaping pharma margins and launch strategies.

White House-Big Pharma Tariff and Pricing Deals in 2026

In early 2026, the White House struck a series of tariff and pricing deals with major pharma firms, linking lower prices for GLP‑1 and other drugs to tariff relief and new distribution channels. Explore how these arrangements are reshaping U.S. pharma pricing, access and global spillovers.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »